BACKGROUND: Monoamine oxidase (MAO) inhibitors can interact with selective serotonin reuptake inhibitors (SSRIs)/serotonin-norepinephrine reuptake inhibitors (SNRIs). There is clinical interest surrounding use of ozanimod with SSRIs/SNRIs because the major metabolites of ozanimod are weak inhibitors of MAO-B in vitro. OBJECTIVE: To evaluate the incidence of treatment-emergent adverse events (TEAEs) potentially related to serotonin accumulation (SA) during concomitant ozanimod and SSRI/SNRI use by performing analyses of data from an open-label, oral ozanimod 0.92 mg trial (DAYBREAK; NCT02576717). METHODS: SA narrow (serotonin syndrome, neuroleptic malignant syndrome, and hyperthermia malignant) and broad (terms potentially associated with SA) MedDRA v24.0 searches were performed using TEAE data from participants with relapsing multiple sclerosis who entered DAYBREAK from phase 3 studies (cutoff February 1, 2022). Incidences of TEAEs matching terms from each search were stratified by SSRI/SNRI use. RESULTS: Of 2257 DAYBREAK participants, 274 (12.1%) used an SSRI/SNRI. No participants had TEAEs matching the SA narrow search terms. There was no significant difference in the percentage of participants with ⩾1 TEAE matching the SA broad search for those on versus off SSRIs/SNRIs (on: 12.4%, n = 34/274; off: 15.6%, n = 310/1982, nominal p = 0.1630). CONCLUSION: MedDRA searches showed no increase in TEAEs potentially associated with SA with concomitant SSRI/SNRI and ozanimod use.

Brain and Mind Centre The University of Sydney Sydney NSW Australia

Bristol Myers Squibb Princeton NJ USA

Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology Perelman School of Medicine University of Pennsylvania Philadelphia PA USA

Center for Neurology Łódź Poland

Collegium Medicum Department of Neurology University of Warmia and Mazury in Olsztyn Olsztyn Poland

Department of Neurology Medical Faculty Heinrich Heine University Düsseldorf Düsseldorf Germany

Department of Neurology Medical University of Vienna Vienna Austria

Mellen Center for MS Treatment and Research Cleveland Clinic Cleveland OH USA

Palacký University Olomouc Olomouc Czech Republic

Vita Salute San Raffaele University and Casa di Cura Igea Milan Italy

Washington University School of Medicine St Louis MO USA

Weill Institute for Neurosciences Department of Neurology University of California San Francisco San Francisco CA USA

000      

00000naa a2200000 a 4500

001      

bmc24007329

003      

CZ-PrNML

005      

20240423155859.0

007      

ta

008      

240412s2024 enk f 000 0|eng||

009      

AR

024    7_

$a 10.1177/13524585231216854 $2 doi

035    __

$a (PubMed)38130041

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a enk

100    1_

$a Naismith, Robert T $u Washington University School of Medicine, St. Louis, MO, USA $1 https://orcid.org/0000000305204283

245    10

$a Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial / $c RT. Naismith, JA. Cohen, A. Bar-Or, G. Comi, KW. Selmaj, HP. Hartung, JK. Sheffield, A. Krakovich, D. Tatosian, CY. Cheng, J. Reardon, V. Khaychuk, JV. Riolo, D. Silva, BA. Cree

520    9_

$a BACKGROUND: Monoamine oxidase (MAO) inhibitors can interact with selective serotonin reuptake inhibitors (SSRIs)/serotonin-norepinephrine reuptake inhibitors (SNRIs). There is clinical interest surrounding use of ozanimod with SSRIs/SNRIs because the major metabolites of ozanimod are weak inhibitors of MAO-B in vitro. OBJECTIVE: To evaluate the incidence of treatment-emergent adverse events (TEAEs) potentially related to serotonin accumulation (SA) during concomitant ozanimod and SSRI/SNRI use by performing analyses of data from an open-label, oral ozanimod 0.92 mg trial (DAYBREAK; NCT02576717). METHODS: SA narrow (serotonin syndrome, neuroleptic malignant syndrome, and hyperthermia malignant) and broad (terms potentially associated with SA) MedDRA v24.0 searches were performed using TEAE data from participants with relapsing multiple sclerosis who entered DAYBREAK from phase 3 studies (cutoff February 1, 2022). Incidences of TEAEs matching terms from each search were stratified by SSRI/SNRI use. RESULTS: Of 2257 DAYBREAK participants, 274 (12.1%) used an SSRI/SNRI. No participants had TEAEs matching the SA narrow search terms. There was no significant difference in the percentage of participants with ⩾1 TEAE matching the SA broad search for those on versus off SSRIs/SNRIs (on: 12.4%, n = 34/274; off: 15.6%, n = 310/1982, nominal p = 0.1630). CONCLUSION: MedDRA searches showed no increase in TEAEs potentially associated with SA with concomitant SSRI/SNRI and ozanimod use.

650    _2

$a lidé $7 D006801

650    _2

$a selektivní inhibitory zpětného vychytávání serotoninu $x škodlivé účinky $7 D017367

650    12

$a inhibitory zpětného vychytávání serotoninu a noradrenalinu $x škodlivé účinky $7 D000068760

650    _2

$a serotonin $7 D012701

650    12

$a roztroušená skleróza $x chemicky indukované $7 D009103

650    _2

$a antidepresiva $x škodlivé účinky $7 D000928

650    12

$a indany $7 D007189

650    12

$a oxadiazoly $7 D010069

655    _2

$a časopisecké články $7 D016428

700    1_

$a Cohen, Jeffrey A $u Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, USA $1 https://orcid.org/0000000192459772

700    1_

$a Bar-Or, Amit $u Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

700    1_

$a Comi, Giancarlo $u Vita-Salute San Raffaele University and Casa di Cura Igea, Milan, Italy $1 https://orcid.org/0000000269891054

700    1_

$a Selmaj, Krzysztof W $u Center for Neurology, Łódź, Poland $u Collegium Medicum, Department of Neurology, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland

700    1_

$a Hartung, Hans-Peter $u Department of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany $u Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia $u Department of Neurology, Medical University of Vienna, Vienna, Austria $u Palacký University Olomouc, Olomouc, Czech Republic

700    1_

$a Sheffield, James K $u Bristol Myers Squibb, Princeton, NJ, USA

700    1_

$a Krakovich, Anthony $u Bristol Myers Squibb, Princeton, NJ, USA

700    1_

$a Tatosian, Daniel $u Bristol Myers Squibb, Princeton, NJ, USA

700    1_

$a Cheng, Chun-Yen $u Bristol Myers Squibb, Princeton, NJ, USA

700    1_

$a Reardon, Jennifer $u Bristol Myers Squibb, Princeton, NJ, USA

700    1_

$a Khaychuk, Vadim $u Bristol Myers Squibb, Princeton, NJ, USA

700    1_

$a Riolo, Jon V $u Bristol Myers Squibb, Princeton, NJ, USA

700    1_

$a Silva, Diego $u Bristol Myers Squibb, Princeton, NJ, USA

700    1_

$a Cree, Bruce Ac $u Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA $1 https://orcid.org/0000000176892533

773    0_

$w MED00006389 $t Multiple sclerosis $x 1477-0970 $g Roč. 30, č. 2 (2024), s. 177-183

856    41

$u https://pubmed.ncbi.nlm.nih.gov/38130041 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20240412 $b ABA008

991    __

$a 20240423155856 $b ABA008

999    __

$a ok $b bmc $g 2081359 $s 1217096

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2024 $b 30 $c 2 $d 177-183 $e 20231221 $i 1477-0970 $m Multiple sclerosis $n Mult Scler $x MED00006389

LZP    __

$a Pubmed-20240412